This image was uploaded in the JPEG format even though it consists of non-photographic data. This information could be stored more efficiently or accurately in the PNG or SVG format. If possible, please upload a PNG or SVG version of this image without compression artifacts, derived from a non-JPEG source (or with existing artifacts removed). After doing so, please tag the JPEG version with {{Superseded|NewImage.ext}} and remove this tag. This tag should not be applied to photographs or scans. If this image is a diagram or other image suitable for vectorisation, please tag this image with {{Convert to SVG}} instead of {{BadJPEG}}. If not suitable for vectorisation, use {{Convert to PNG}}. For more information, see {{BadJPEG}}.
Miêu tả
Miêu tảFimmu-11-579250-g004.jpg
English: Vaccine platforms being employed for SARS-CoV-2 vaccine design. This figure illustrates the different vaccine approaches being taken for the design of human SARS-CoV-2 vaccines. Whole virus vaccines include both attenuated and inactivated forms of the virus and subunits of inactivated virus can also be used. Protein and peptide subunit vaccines are usually combined with an adjuvant in order to enhance immunogenicity. The main emphasis in SARS-CoV-2 vaccine development has been on using the whole spike protein in its trimeric form or components of it, such as the RBD region. Multiple non-replicating viral vector vaccines have been developed, particularly focused on adenovirus; while there has been less emphasis on the replicating viral vector constructs. Nucleic acid-based approaches include DNA and mRNA vaccines, often packaged into nanocarriers such as virus-like particles (VLPs) and lipid nanoparticles (LNPs). Nanoparticle and VLP vaccines can also have antigen attached to their surface or combined in their core. The immune cell therapy approach uses genetically modified SARS-CoV-2-specific cytotoxic T cells and dendritic cells expressing viral antigens to protect against SARS-CoV-2 infection. Each of these vaccine approaches has benefits and disadvantages in terms of cost and ease of production, safety profile and immunogenicity, and it remains to be seen which of the many candidates in development protect against COVID-19.
Ngày
Nguồn gốc
Flanagan KL, Best E, Crawford NW, Giles M, Koirala A, Macartney K, Russell F, Teh BW and Wen SCH (2020) Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines. Front. Immunol. 11:579250.
Katie L. Flanagan, Emma Best, Nigel W. Crawford, Michelle Giles, Archana Koirala, Kristine Macartney, Fiona Russell, Benjamin W. Teh, and Sophie CH Wen, on behalf of the Australasian Society for Infectious Diseases (ASID) Vaccination Special Interest group (VACSIG)
chia sẻ – sao chép, phân phối và chuyển giao tác phẩm
pha trộn – để chuyển thể tác phẩm
Theo các điều kiện sau:
ghi công – Bạn phải ghi lại tác giả và nguồn, liên kết đến giấy phép, và các thay đổi đã được thực hiện, nếu có. Bạn có thể làm các điều trên bằng bất kỳ cách hợp lý nào, miễn sao không ám chỉ rằng người cho giấy phép ủng hộ bạn hay việc sử dụng của bạn.
https://creativecommons.org/licenses/by/4.0CC BY 4.0 Creative Commons Attribution 4.0 truetrue
Chú thích
Ghi một dòng giải thích những gì có trong tập tin này
Vaccine platforms being employed for SARS-CoV-2 vaccine design.
Uploaded a work by Katie L. Flanagan, Emma Best, Nigel W. Crawford, Michelle Giles, Archana Koirala, Kristine Macartney, Fiona Russell, Benjamin W. Teh, and Sophie CH Wen, on behalf of the Australasian Society for Infectious Diseases (ASID) Vaccination Special Interest group (VACSIG) from Flanagan KL, Best E, Crawford NW, Giles M, Koirala A, Macartney K, Russell F, Teh BW and Wen SCH (2020) Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines. Front. Immunol. 11:579...
Trang sử dụng tập tin
Có 1 trang tại Wikipedia tiếng Việt có liên kết đến tập tin (không hiển thị trang ở các dự án khác):